Effect of two novel CGRP-binding compounds in a closed cranial window rat model

Area of Science:

• Neuroscience
• Pharmacology
• Vascular Biology

Background:

• Calcitonin gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology.
• CGRP receptor antagonists are established migraine treatments.
• Novel CGRP binding molecules offer potential alternative therapeutic strategies.

Purpose of the Study:

• To evaluate the in vivo efficacy of two novel CGRP binding molecules: RNA-Spiegelmer (NOX-C89) and a monoclonal CGRP antibody.
• To investigate their effects on cranial artery diameter in a rat closed cranial window model.
• To compare their inhibitory actions against CGRP-induced and electrically stimulated arterial dilation.

Main Methods:

• Utilized a closed cranial window model in anesthetized rats.
• Measured changes in dural and pial artery diameter and mean arterial blood pressure.
• Administered CGRP or used electrical stimulation to induce arterial dilation.
• Assessed the inhibitory effects of pre-treatment with RNA-Spiegelmer or CGRP antibody.

Main Results:

• Neither RNA-Spiegelmer nor CGRP antibody alone affected arterial diameter or blood pressure.
• Both agents significantly inhibited CGRP-induced dural and pial artery vasodilatation.
• Neither molecule significantly inhibited arterial dilation induced by electrical stimulation.
• CGRP scavengers effectively blocked circulating CGRP effects but not CGRP release from nerve fibers.

Conclusions:

• Novel CGRP scavengers (RNA-Spiegelmer and CGRP antibody) are effective in blocking circulating CGRP.
• These molecules show potential as migraine therapeutics by targeting CGRP directly.
• Their lack of effect on electrically stimulated dilation suggests a specific mechanism targeting CGRP itself, not its release.